復星醫藥(600196.SH):控股子公司復宏漢霖擬授予Accord在區域內就HLX02開展獨家商業化許可
格隆匯 9 月 30日丨復星醫藥(600196.SH)公佈,控股子公司上海復宏漢霖生物技術股份有限公司(以下簡稱“復宏漢霖”)授予AccordHealthcareInc.(以下簡稱“Accord”)在區域內(即美國、加拿大,下同)就HLX02(即注射用曲妥珠單抗;以下簡稱“該產品”)獨家商業化(包括但不限於出口、進口、推廣、儲存、要約出售及分銷等商業化行為)及與之相關權利的許可。
2020年9月29日,公司控股子公司復宏漢霖與Accord簽訂《許可條款書》,復宏漢霖擬授予Accord在區域內就該產品開展獨家商業化(包括但不限於出口、進口、推廣、儲存、要約出售及分銷等商業化行為)及與之相關權利的許可。就本次合作的具體安排尚待雙方進一步商議確定,有關本次合作須以雙方簽訂最終協議並以該等協議約定事項為準。
本次合作不構成關聯交易,亦不構成《上市公司重大資產重組管理辦法》規定的重大資產重組。
本次合作無需提請本公司董事會或股東大會批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.